Bio-Techne Corporation (NASDAQ:TECH ) Q4 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants David Clair - VP of Investor Relations & Corporate Development James T. Hippel - Executive VP of Finance & CFO Kim Kelderman - CEO, President & Director Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Louis Leonard - UBS Investment Bank, Research Division Kyle Boucher - TD Cowen, Research Division Matthew Richard Larew - William Blair & Company L.L.C.
The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
TECH tops Q4 EPS estimates and posts solid revenues, but shrinking margins and operating loss drag shares lower.
![]() TE1 2 months ago | Other | €0.07 Per Share |
![]() TE1 5 months ago | Other | €0.07 Per Share |
![]() TE1 9 months ago | Other | €0.07 Per Share |
![]() TE1 11 months ago | Other | €0.07 Per Share |
![]() TE1 10 May 2024 | Other | €0.07 Per Share |
5 Nov 2025 (In 2 months) Date | | 0.43 Cons. EPS | - EPS |
28 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
13 Aug 2025 13 Aug 2025 Date | | 0.5 Cons. EPS | - EPS |
6 Aug 2025 Date | | 0.5 Cons. EPS | - EPS |
5 Aug 2025 Date | | - Cons. EPS | - EPS |
![]() TE1 2 months ago | Other | €0.07 Per Share |
![]() TE1 5 months ago | Other | €0.07 Per Share |
![]() TE1 9 months ago | Other | €0.07 Per Share |
![]() TE1 11 months ago | Other | €0.07 Per Share |
![]() TE1 10 May 2024 | Other | €0.07 Per Share |
5 Nov 2025 (In 2 months) Date | | 0.43 Cons. EPS | - EPS |
28 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
13 Aug 2025 13 Aug 2025 Date | | 0.5 Cons. EPS | - EPS |
6 Aug 2025 Date | | 0.5 Cons. EPS | - EPS |
5 Aug 2025 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Kim Kelderman CEO | XBER Exchange | US09073M1045 ISIN |
US Country | 3,100 Employees | 18 Aug 2025 Last Dividend | 30 Nov 2022 Last Split | 9 Feb 1989 IPO Date |
Bio-Techne Corporation operates at the forefront of the life science sector, providing a comprehensive range of products and services crucial for research, clinical diagnostics, and therapeutic development. With a global footprint, the company serves a diverse clientele spread across the United States, the United Kingdom, rest of Europe, Middle East, Africa, Greater China, and the rest of the Asia-Pacific region. Bio-Techne is structured into two main operational segments: Protein Sciences, and Diagnostics and Genomics, each addressing different needs within the life sciences and diagnostics sectors. Originally established in 1976 under the name Techne Corporation, the organization underwent a rebranding to Bio-Techne Corporation in November 2014 and is based in Minneapolis, Minnesota. This strategic evolution reflects its broadened focus beyond its initial scope, signaling its expansion into a comprehensive suite of technologies and services catering to the dynamic requirements of biological research and clinical diagnostics.
Bio-Techne Corporation distinguishes itself through its broad portfolio of products and services across two main segments: